Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | The benefits of investigating allogeneic CAR-T products for patients with B-ALL

Martina Sersch, MD, Gracell Biotechnologies, San Diego, CA, briefly discusses the benefit of allogeneic CAR-T products for patients with B-cell acute lymphoblastic leukemia (B-ALL). Dr Sersch first highlights the rapid disease progression that patients with B-ALL face, and then goes on to discuss the benefits of further investigating allogeneic, readily available CAR-T products. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.